Fuchs Endothelial Corneal Dystrophy (FECD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Fuchs Endothelial Corneal Dystrophy Marketed and Pipeline Drugs Report Overview
Fuchs Endothelial Corneal Dystrophy (FECD) is a bilateral, slowly progressive, often asymmetric corneal disease. FECD is a sporadic or autosomal dominant dystrophy involving the endothelial layer of the cornea.
Key Mechanisms of Action (Pipeline) | · Enzyme Inhibitor
· Receptor Agonist · Protein and Peptide Inhibitor · Transporter Inhibitor |
Key Molecule Types (Pipeline) | · Small Molecule
· Biologic |
Key Routes of Administration (Pipeline) | · Topical
· Oral · Injection |
Top Sponsors (Marketed and Pipeline Drugs) | · Massachusetts Eye and Ear Infirmary
· Trefoil Therapeutics · Kowa Co · Price Vision Group · Invirsa Inc · University Hospital Erlangen |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Fuchs Endothelial Corneal Dystrophy Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Fuchs Endothelial Corneal Dystrophy.
The report also provides actionable insights into the clinical and commercial landscapes of Fuchs Endothelial Corneal Dystrophy drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the pipeline drugs for Fuchs Endothelial Corneal Dystrophy include receptor agonist, enzyme inhibitor, protein and peptide inhibitor, and transporter inhibitor. Most of the pipeline drugs followed enzyme inhibitor MoA in 2023 in the Fuchs Endothelial Corneal Dystrophy market.
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Fuchs Endothelial Corneal Dystrophy Pipeline Drugs
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Market Segmentation by Routes of Administration
The key RoA of Fuchs Endothelial Corneal Dystrophy pipeline drugs include oral, injection, and topical. Most pipeline drugs that were available for Fuchs Endothelial Corneal Dystrophy were topical formulations.
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Fuchs Endothelial Corneal Dystrophy Marke Pipeline ted Drugs, Download a Free Report Sample
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Market Segmentation by Molecule Types
In 2023, biologics and small molecules were being developed in equal numbers in the FECD pipeline.
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Fuchs Endothelial Corneal Dystrophy Pipeline Drugs, Download a Free Report Sample
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Market Segmentation by Molecule Types
In 2023, biologics and small molecules were being developed in equal numbers in the FECD pipeline.
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Fuchs Endothelial Corneal Dystrophy Pipeline Drugs, Download a Free Report Sample
Fuchs Endothelial Corneal Dystrophy Marketed and Pipeline Drugs Market - Competitive Landscape
A few of the top sponsors in the Fuchs Endothelial Corneal Dystrophy marketed and pipeline drugs market are Massachusetts Eye and Ear Infirmary, Trefoil Therapeutics, Kowa Co, Price Vision Group, Invirsa Inc, and University Hospital Erlangen among others. Massachusetts Eye and Ear Infirmary sponsored the highest number of trials in 2023. Roche conducted the highest number of Phase III trials, while the highest number of Phase II trials was sponsored by AbbVie.
Fuchs Endothelial Corneal Dystrophy Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for More Sponsor Insights into the Fuchs Endothelial Corneal Dystrophy Marketed and Pipeline Drugs Market
Segments Covered in the Report
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonist
- Enzyme Inhibitor
- Protein and Peptide Inhibitor
- Transporter Inhibitor
Fuchs Endothelial Corneal Dystrophy Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologic
- Small Molecule
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Understand the trends shaping and driving the Fuchs Endothelial Corneal Dystrophy market to develop business strategies.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Fuchs Endothelial Corneal Dystrophy market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which was the leading MoA for Fuchs Endothelial Corneal Dystrophy pipeline drugs in 2023?
Most of the pipeline drugs followed enzyme inhibitor MoA in 2023 in the Fuchs Endothelial Corneal Dystrophy market.
-
Which was the leading molecule type for Fuchs Endothelial Corneal Dystrophy pipeline drugs in 2023?
In 2023, biologics and small molecules were being developed in equal numbers in the FECD pipeline drugs market.
-
Which are the top sponsors in the Fuchs Endothelial Corneal Dystrophy marketed and pipeline drugs market?
A few of the top sponsors in the Fuchs Endothelial Corneal Dystrophy marketed and pipeline drugs market are Massachusetts Eye and Ear Infirmary, Trefoil Therapeutics, Kowa Co, Price Vision Group, Invirsa Inc, and University Hospital Erlangen among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.